Mediwound AI Stock Analysis
Want to see MDWD full AI Analyst Report?
Mediwound (MDWD) AI Stock Analysis
Mediwound
(NASDAQ:MDWD)
The score is primarily weighed down by weak financial performance (contracting revenue, large losses, and significant ongoing cash burn). Technicals are mixed with the stock trading below key moving averages, while the earnings call provided meaningful development and demand positives that are tempered by funding uncertainty and supply constraints. Valuation offers limited support due to negative earnings and no dividend yield provided.
Mediwound (MDWD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $176.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 120.90K
- Price to Earnings (P/E)
- -7.5
- Beta (1Y)
- 0.85
- Revenue Growth
- -52.19%
- EPS Growth
- 3.91%
- Country
- US
- Employees
- 121
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Mediwound Business Overview & Revenue Model
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The compan...
How the Company Makes Money
MediWound generates revenue primarily through (1) product sales of its burn debridement therapy NexoBrid in markets where it is commercialized and reimbursed, and (2) collaboration, license, and service-related income tied to partnerships for develop...
Mediwound Earnings Call Summary
The call had meaningful operational and development positives, including strong NexoBrid demand, positive VALUE trial safety reviews, progress toward enrollment and additional funding for NexoBrid programs. However, these were offset by lower revenue, widening operating and adjusted EBITDA losses, substantial cash burn, supply-constrained product sales, and uncertainty around U.S. government funding that affects the 2026 outlook and a significant portion of 2027 guidance. Overall, the positive and negative factors were relatively balanced.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said the VALUE trial’s current enrollment target is 216 patients across approximately 40 sites, with enrollment expected to be completed by the end of the first quarter of 2027; the interim sample size reassessment is planned after treatment of 140-ish patients to confirm 85% statistical power, followed by around 3 months of treatment and another couple of weeks of aggregating the data, with top line results expected in mid-2027. Management said 95% of the sites are open, expanded NexoBrid facility work is expected to be completed in the fourth quarter of 2026, commercial supply remains expected in the second half of 2027, and there is some cushion in that 6-month period, but supply is not expected earlier. The company said its 2026 revenue outlook depends on ongoing U.S. government funding discussions, while a substantial portion of anticipated 2026 revenue is tied to the planned U.S.-based facility; the $24 million to $26 million guidance has a significant part tied to that facility. Management also described approximately $1 billion in U.S. peak sales across 3 chronic wound categories, a 50-patient DFU study, and an additional $3.3 million award bringing the room-temperature-stable NexoBrid program’s total budget to $21.8 million.
Mediwound Financial Statement Overview
Summary
Overall financial performance is weak: revenue has contracted materially (TTM ~$10.0M vs ~$17.0M in 2025 and ~$20.2M in 2024) and profitability is deeply negative (TTM net margin ~-235%) with sizable operating/free-cash burn (TTM OCF about -$26.4M; FCF about -$32.6M). The balance sheet is comparatively steadier with moderate leverage (debt-to-equity ~0.26), but equity has declined alongside ongoing losses.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
21Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.01M | 16.96M | 20.22M | 18.69M | 26.50M | 23.76M |
| Gross Profit | 1.95M | 3.25M | 2.63M | 3.58M | 13.16M | 8.77M |
| EBITDA | -24.98M | -21.47M | -27.93M | -4.80M | -18.25M | -11.38M |
| Net Income | -23.51M | -23.88M | -30.22M | -6.72M | -19.60M | -13.55M |
Balance Sheet | ||||||
| Total Assets | 65.50M | 86.25M | 73.50M | 66.46M | 50.02M | 19.74M |
| Cash, Cash Equivalents and Short-Term Investments | 27.85M | 53.14M | 43.16M | 41.54M | 33.90M | 11.05M |
| Total Debt | 8.30M | 8.15M | 6.93M | 6.35M | 846.00K | 1.39M |
| Total Liabilities | 33.70M | 42.62M | 42.34M | 34.86M | 39.10M | 24.33M |
| Stockholders Equity | 31.79M | 43.63M | 31.15M | 31.59M | 10.91M | -4.58M |
Cash Flow | ||||||
| Free Cash Flow | -32.56M | -20.04M | -19.90M | -16.93M | -12.44M | -9.40M |
| Operating Cash Flow | -26.41M | -14.53M | -13.62M | -10.46M | -11.88M | -8.92M |
| Investing Cash Flow | -989.69K | -19.54M | -8.40M | -34.32M | -481.00K | 3.55M |
| Financing Cash Flow | -351.94K | 29.62M | 19.39M | 22.92M | 35.76M | -1.05M |
Mediwound Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Positive. The current price of 13.68 is above the 20-day moving average (MA) of 13.27, above the 50-day MA of 13.21, and below the 200-day MA of 15.00, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 53.79 is Neutral, neither overbought nor oversold. The STOCH value of 42.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDWD.
Mediwound Risk Analysis
Mediwound disclosed 58 risk factors in its most recent earnings report. Mediwound reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksMediwound Peers Comparison
Overall Rating
HUMA57Neutral
VRCA46Neutral
MDWD46Neutral
ALDX41Neutral
CRBP40Underperform
GALT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | $139.18M | -1.10 | -591.73% | ― | 52.51% | -82.58% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $53.94M | -1.34 | -442.78% | ― | -25.75% | 35.30% | |
| 46Neutral | $176.61M | -7.52 | -61.68% | ― | -52.19% | 3.91% | |
| 41Neutral | $41.88M | -2.17 | >-0.01% | ― | ― | 56.04% | |
| 40Underperform | $62.03M | -0.47 | -100.96% | ― | ― | -10.49% | |
| 40Underperform | $293.55M | -8.48 | 21.65% | ― | ― | 42.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MDWD | Mediwound | 13.68 | -4.18 | -23.40% | |
| GALT | Galectin Therapeutics (GALT) | 2.91 | -2.83 | -49.30% | |
| ALDX | Aldeyra Therapeutics | 0.69 | -4.17 | -85.74% | |
| CRBP | Corbus Pharmaceuticals Holdings | 3.01 | -8.81 | -74.53% | |
| VRCA | Verrica Pharmaceuticals | 3.14 | -1.34 | -29.91% | |
| HUMA | Humacyte | 0.50 | -0.67 | -57.18% |
Mediwound Corporate Events
MediWound Reports Third-Quarter 2026 Results and Corporate Update
On November 12, 2026, MediWound reported third-quarter revenue of $3.6 million, down from $5.4 million a year earlier, while gross profit rose to $1.0 million, or 28.5% of revenue, from $0.9 million, or 16.5%. Research and development expense increas...
MediWound Announces $17.25 Million Share Offering After Full Option Exercise
MediWound Ltd. is an Israeli biotechnology company focused on biological treatments for severe burns and chronic wounds, serving the specialized wound-care market. Its commercial and investigational products are intended to support non-surgical wound...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
